TAYEBI Mohamed
Email : tayebi.mo@uit.ac.ma
Établissement : Faculté des sciences
Laboratoire : Géosciences et Ressources Naturelles
← Retour au laboratoire
📚 Publications Scopus — Total : 43
| Titre | Année | 🔗 Voir |
|---|---|---|
| Efficacy and tolerability of metformin as an adjuvant therapy in patients with relapse-remitting multiple sclerosis receiving interferon Beta 1a: A randomized pilot trial | 2026 | 🔗 Voir |
| Exploring Neural Stem Cell Therapies as Innovative Treatments for Glioblastoma | 2025 | 🔗 Voir |
| When less is more: The association between the expression of polymorphic CYPs and AFB1-induced HCC | 2024 | 🔗 Voir |
| Epigenetic tuning of tumour-associated macrophages (TAMs): A potential approach in hepatocellular carcinoma (HCC) immunotherapy | 2024 | 🔗 Voir |
| The impact of metformin use on the outcomes of relapse-remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open-label randomized controlled trial | 2024 | 🔗 Voir |
| Corrigendum to “NEAT1: Culprit lncRNA linking PIG[sbnd]C, MSLN, and CD80 in triple-negative breast cancer” [Life Sci., volume 299 (2022) 120523] (Life Sciences (2022) 299, (S0024320522002235), (10.1016/j.lfs.2022.120523)) | 2023 | 🔗 Voir |
| Corrigendum to “MALAT-1: LncRNA ruling miR-182/PIG-C/mesothelin triad in triple negative breast cancer” [Pathol. Res. Pract. 216 (2020) 153274](S0344033820321294)(10.1016/j.prp.2020.153274) | 2023 | 🔗 Voir |
| Virtual Screening and Biological Evaluation of Potential PD-1/PD-L1 Immune Checkpoint Inhibitors as Anti-Hepatocellular Carcinoma Agents | 2023 | 🔗 Voir |
| Thymoquinone, a Novel Multi-Strike Inhibitor of Pro-Tumorigenic Breast Cancer (BC) Markers: CALR, NLRP3 Pathway and sPD-L1 in PBMCs of HR+ and TNBC Patients | 2023 | 🔗 Voir |
| What's your cup of tea? The role of herbal compounds in the management of multiple sclerosis | 2023 | 🔗 Voir |
| Inflammasomes in breast cancer: The ignition spark of progression and resistance? | 2023 | 🔗 Voir |
| Rs205764 and rs547311 in linc00513 may influence treatment responses in multiple sclerosis patients: A pharmacogenomics Egyptian study | 2023 | 🔗 Voir |
| The Monocyte, a Maestro in the Tumor Microenvironment (TME) of Breast Cancer | 2022 | 🔗 Voir |
| A cutting-edge immunomodulatory interlinkage between HOTAIR and MALAT1 in tumor-associated macrophages in breast cancer: A personalized immunotherapeutic approach | 2022 | 🔗 Voir |
| Small Molecule Inhibitors for Hepatocellular Carcinoma: Advances and Challenges | 2022 | 🔗 Voir |
| NEAT1: Culprit lncRNA linking PIG-C, MSLN, and CD80 in triple-negative breast cancer | 2022 | 🔗 Voir |
| CXCR2 Small-Molecule Antagonist Combats Chemoresistance and Enhances Immunotherapy in Triple-Negative Breast Cancer | 2022 | 🔗 Voir |
| Scavenging the hidden impacts of non-coding RNAs in multiple sclerosis | 2021 | 🔗 Voir |
| Genetic heterogeneity, therapeutic hurdle confronting sorafenib and immune checkpoint inhibitors in hepatocellular carcinoma | 2021 | 🔗 Voir |
| Long non-coding RNAs XIST and MALAT1 hijack the PD-L1 regulatory signaling pathway in breast cancer subtypes | 2021 | 🔗 Voir |
| miR-155 and functional proteins of CD8+ T cells as potential prognostic biomarkers for relapsing-remitting multiple sclerosis | 2021 | 🔗 Voir |
| Oleuropin controls miR-194/XIST/PD-L1 loop in triple negative breast cancer: New role of nutri-epigenetics in immune-oncology | 2021 | 🔗 Voir |
| Thymoquinone: A tie-breaker in sars-cov2-infected cancer patients? | 2021 | 🔗 Voir |
| From Whole Blood to Isolated Pro-Metastasis Immune Cells: An Ex Vivo Approach to Isolate and Manipulate Immune Cells Contributing to Tumor Metastasis | 2021 | 🔗 Voir |
| Pivotal role of long non-coding ribonucleic acid-X-inactive specific transcript in regulating immune checkpoint programmed death ligand 1 through a shared pathway between miR-194-5p and miR-155-5p in hepatocellular carcinoma | 2020 | 🔗 Voir |
| GPI-AP: Unraveling a New Class of Malignancy Mediators and Potential Immunotherapy Targets | 2020 | 🔗 Voir |
| MALAT-1: LncRNA ruling miR-182/PIG-C/mesothelin triad in triple negative breast cancer | 2020 | 🔗 Voir |
| XIST and TSIX: Novel Cancer Immune Biomarkers in PD-L1-Overexpressing Breast Cancer Patients | 2020 | 🔗 Voir |
| Methylation in MIRLET7A3 gene induces the expression of IGF-II and its mRNA binding proteins IGF2BP-2 and 3 in Hepatocellular carcinoma | 2019 | 🔗 Voir |
| Destabilizing the interplay between miR-1275 and IGF2BPs by Tamarix articulata and quercetin in hepatocellular carcinoma | 2018 | 🔗 Voir |
| Behind the curtain of non-coding RNAs; Long non-coding RNAs regulating hepatocarcinogenesis | 2018 | 🔗 Voir |
| MiR-615-5p depresses natural killer cells cytotoxicity through repressing IGF-1R in hepatocellular carcinoma patients | 2017 | 🔗 Voir |
| MicroRNA-486-5p enhances hepatocellular carcinoma tumor suppression through repression of IGF-1R and its downstream mTOR, STAT3 and c-Myc | 2016 | 🔗 Voir |
| Interplay between microRNA-17-5p, insulin-like growth factor-II through binding protein-3 in hepatocellular carcinoma | 2016 | 🔗 Voir |
| Contradicting interplay between insulin-like growth factor-1 and miR-486-5p in primary NK cells and hepatoma cell lines with a contemporary inhibitory impact on HCC tumor progression | 2016 | 🔗 Voir |
| Epigenetic regulation of insulin-like growth factor axis in hepatocellular carcinoma | 2016 | 🔗 Voir |
| miR-34a: Multiple opposing targets and one destiny in hepatocellular carcinoma | 2016 | 🔗 Voir |
| Transcriptional activation of the IGF-II/IGF-1R axis and inhibition of IGFBP-3 by miR-155 in hepatocellular carcinoma | 2015 | 🔗 Voir |
| MiR-1275: A single microRNA that targets the three IGF2-mRNA-binding proteins hindering tumor growth in hepatocellular carcinoma | 2015 | 🔗 Voir |
| A pleiotropic effect of the single clustered hepatic metastamiRs miR-96-5p and miR-182-5p on insulin-like growth factor II, insulin-like growth factor-1 receptor and insulin-like growth factor-binding protein-3 in hepatocellular carcinoma | 2015 | 🔗 Voir |
| Repression of miR-17-5p with elevated expression of E2F-1 and c-MYC in non-metastatic hepatocellular carcinoma and enhancement of cell growth upon reversing this expression pattern | 2013 | 🔗 Voir |
| MiR-615-5p is restrictedly expressed in cirrhotic and cancerous liver tissues and its overexpression alleviates the tumorigenic effects in hepatocellular carcinoma | 2012 | 🔗 Voir |
| Expression of insulin-like growth factor-II, matrix metalloproteinases, and their tissue inhibitors as predictive markers in the peripheral blood of HCC patients | 2011 | 🔗 Voir |